| External factors: | zofenoprilat |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay |
| Description: | Zofenoprilat inhibits endothelial senescence.CVEC were incubated with different concentrations of zofenoprilat (1–10uM) and FGF-2 (20 ng/ml) for 3 days. Cell senescence was evaluated by SA-β-gal staining. Representative pictures of SA-β-gal-positive cells (blue) are reported. After 3 days in culture, the number of SA-β-gal-positive cells in a total of 400 cells was counted (n=3). |
| Target gene: | FGF-2//TERT |
| R-EF-Target gene: | Activation//Upregulation |
| Official symbol(s): | FGF2//TERT |
| Target gene experiment: | qRT-PCR//Western blot |
| Target gene description: | Zofenoprilat increased TERT mRNA (6-fold), approaching the level reached by FGF-2 (20 ng/ml).whereas that produced by FGF-2 was rapid and declined with time. |
| Regulatory pathway: | Akt//eNOS |
| R-EF-Pathway: | Activation//Activation |
| Official symbol(s): | AKT1//NOS3 |
| Pathway experiment: | qRT-PCR//Western blot |
| Pathway description: | Zofenoprilat (10um) enhanced the phosphorylation of Akt . This activation was slow but persistent (up to 6 h).Assessment of eNOS activation downstream of Akt, measured by phosphorylation of eNOS in Ser1177, demonstrated that zofenoprilat increased eNOS activation . |
Annotation: